Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence.

IF 8.2 1区 医学 Q1 HEMATOLOGY Haematologica Pub Date : 2024-12-19 DOI:10.3324/haematol.2024.286420
Rajani P Brandsen, Roselie M H Diederen, Gizem Kocabas, Erfan Nur, Arjan Malekzadeh, Reinier O Schlingemann, Bart J Biemond
{"title":"Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence.","authors":"Rajani P Brandsen, Roselie M H Diederen, Gizem Kocabas, Erfan Nur, Arjan Malekzadeh, Reinier O Schlingemann, Bart J Biemond","doi":"10.3324/haematol.2024.286420","DOIUrl":null,"url":null,"abstract":"<p><p>Sickle cell retinopathy (SCR) is a complication of sickle cell disease (SCD) and can drastically impair visual acuity. Screening for SCR is therefore recommended, but evidence for optimal screening frequency on an individual level is lacking. This scoping review mapped the current evidence on risk factors for SCR and sickle cell maculopathy (SCM). A literature search (in Medline(Ovid), Embase(Ovid) and Scopus) resulted in 67 included articles, which covered demographic risk factors, genetic risk factors, systemic therapy, correlations with other forms of SCD-related organ damage and hematological risk factors. SCR risk factors include older age, male sex, HbSC genotype, hemolysis and HbF% 15%) patients to ensure comprehensive yet proportionate ophthalmic care. However, to elucidate the sense and nonsense of screening, future studies are needed on the role of interventions for SCR and the long-term consequences of SCM.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"0"},"PeriodicalIF":8.2000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2024.286420","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Sickle cell retinopathy (SCR) is a complication of sickle cell disease (SCD) and can drastically impair visual acuity. Screening for SCR is therefore recommended, but evidence for optimal screening frequency on an individual level is lacking. This scoping review mapped the current evidence on risk factors for SCR and sickle cell maculopathy (SCM). A literature search (in Medline(Ovid), Embase(Ovid) and Scopus) resulted in 67 included articles, which covered demographic risk factors, genetic risk factors, systemic therapy, correlations with other forms of SCD-related organ damage and hematological risk factors. SCR risk factors include older age, male sex, HbSC genotype, hemolysis and HbF% 15%) patients to ensure comprehensive yet proportionate ophthalmic care. However, to elucidate the sense and nonsense of screening, future studies are needed on the role of interventions for SCR and the long-term consequences of SCM.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
镰状细胞视网膜病变和黄斑病变的临床和实验室危险因素:当前证据的范围审查。
镰状细胞视网膜病变(SCR)是镰状细胞病(SCD)的并发症,可严重损害视力。因此,推荐进行SCR筛查,但缺乏在个体水平上最佳筛查频率的证据。本综述概述了SCR和镰状细胞黄斑病(SCM)危险因素的现有证据。文献检索(Medline(Ovid)、Embase(Ovid)和Scopus)共纳入67篇文章,涵盖人口危险因素、遗传危险因素、全身治疗、与其他形式scd相关器官损伤的相关性以及血液危险因素。SCR的危险因素包括年龄较大、男性、HbSC基因型、溶血和HbF(15%)患者,以确保全面而适当的眼科护理。然而,为了阐明筛查的意义和无意义,未来需要对SCR干预措施的作用和SCM的长期后果进行研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Haematologica
Haematologica 医学-血液学
CiteScore
14.10
自引率
2.00%
发文量
349
审稿时长
3-6 weeks
期刊介绍: Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.
期刊最新文献
Very long-term remission with azacitidine in VEXAS syndrome. More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on "Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism" and on "The different faces of thrombotic thrombocytopenic purpura". Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study. Acute promyelocytic leukemia with TTMV::RARA fusion potentially responds to all-trans retinoic acid/arsenic trioxide treatment. Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1